244 related articles for article (PubMed ID: 15614015)
1. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system.
Kurtz TW; Pravenec M
J Hypertens; 2004 Dec; 22(12):2253-61. PubMed ID: 15614015
[TBL] [Abstract][Full Text] [Related]
2. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
3. New treatment strategies for patients with hypertension and insulin resistance.
Kurtz TW
Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
[TBL] [Abstract][Full Text] [Related]
4. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
[TBL] [Abstract][Full Text] [Related]
5. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator.
Kurtz TW
Acta Diabetol; 2005 Apr; 42 Suppl 1():S9-16. PubMed ID: 15868121
[TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly.
Jugdutt BI
Clin Interv Aging; 2010 Dec; 5():403-16. PubMed ID: 21152242
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity.
Schupp M; Clemenz M; Gineste R; Witt H; Janke J; Helleboid S; Hennuyer N; Ruiz P; Unger T; Staels B; Kintscher U
Diabetes; 2005 Dec; 54(12):3442-52. PubMed ID: 16306360
[TBL] [Abstract][Full Text] [Related]
8. Beyond the classic angiotensin-receptor-blocker profile.
Kurtz TW
Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S19-26. PubMed ID: 18580862
[TBL] [Abstract][Full Text] [Related]
9. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
Clasen R; Schupp M; Foryst-Ludwig A; Sprang C; Clemenz M; Krikov M; Thöne-Reineke C; Unger T; Kintscher U
Hypertension; 2005 Jul; 46(1):137-43. PubMed ID: 15939809
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin inhibition stimulates PPARgamma and the release of visfatin.
Storka A; Vojtassakova E; Mueller M; Kapiotis S; Haider DG; Jungbauer A; Wolzt M
Eur J Clin Invest; 2008 Nov; 38(11):820-6. PubMed ID: 19021699
[TBL] [Abstract][Full Text] [Related]
11. Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives.
Sanchez RA; Masnatta LD; Pesiney C; Fischer P; Ramirez AJ
J Hypertens; 2008 Dec; 26(12):2393-8. PubMed ID: 19008718
[TBL] [Abstract][Full Text] [Related]
12. Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-δ activation.
Li L; Luo Z; Yu H; Feng X; Wang P; Chen J; Pu Y; Zhao Y; He H; Zhong J; Liu D; Zhu Z
Diabetes; 2013 Mar; 62(3):762-74. PubMed ID: 23238297
[TBL] [Abstract][Full Text] [Related]
13. Rationale for double renin-angiotensin-aldosterone system blockade.
Unger T; Stoppelhaar M
Am J Cardiol; 2007 Aug; 100(3A):25J-31J. PubMed ID: 17666194
[TBL] [Abstract][Full Text] [Related]
14. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders.
Yamagishi S; Nakamura K; Matsui T
Curr Mol Med; 2007 Aug; 7(5):463-9. PubMed ID: 17691961
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.
Benndorf RA; Rudolph T; Appel D; Schwedhelm E; Maas R; Schulze F; Silberhorn E; Böger RH
Metabolism; 2006 Sep; 55(9):1159-64. PubMed ID: 16919533
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system.
Tuck ML
Curr Hypertens Rep; 2005 Aug; 7(4):240-3. PubMed ID: 16061040
[TBL] [Abstract][Full Text] [Related]
17. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
[TBL] [Abstract][Full Text] [Related]
18. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
Yamagishi S; Takenaka K; Inoue H
Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710
[TBL] [Abstract][Full Text] [Related]
19. Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia.
Kasahara Y; Taguchi A; Uno H; Nakano A; Nakagomi T; Hirose H; Stern DM; Matsuyama T
Brain Res; 2010 Jun; 1340():70-80. PubMed ID: 20388500
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan increases localization of glucose transporter 4 to the plasma membrane and increases glucose uptake via peroxisome proliferator-activated receptor γ in 3T3-L1 adipocytes.
Furukawa H; Mawatari K; Koyama K; Yasui S; Morizumi R; Shimohata T; Harada N; Takahashi A; Nakaya Y
Eur J Pharmacol; 2011 Jun; 660(2-3):485-91. PubMed ID: 21514293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
